Pfizer and other pharmaceutical companies still increase its drugs price in U.S. despite criticism. Mounting objection from politicans and lawmakers is unable to stop market power of companies in the multi-billion dollar phamaceutical industry.
Breaking News
- Donald Trump Is Eyeing Middle-Class Tax Cut Should He Take Down Joe Biden and Win Back the White House: Report
- Red Lobster Explores Bankruptcy Amid Mounting Debt: Reports
- US Plans to Lift Tariff Exceptions to Dominant Chinese Solar Panel Imports as Biden Accuses Beijing of 'Cheating' on Its Steel Trade Pactices
Pfizer Inc (PFE.N) said it would buy Hospira Inc (HSP.N) for about $15 billion to boost its portfolio of generic injectable drugs and copies of biotech medicines.
Subscribe to VCpost newsletter
Most Popular
- China Hits 2 U.S. Defense Companies With Sanctions For Selling Military Weapons to Taiwan
- SSDI Payment April 2024: Who Will Receive Social Security Benefits Today?
- UPDATE: Google Employees Arrested and Fired After Staging Protests Over Company's Project Nimbus Deal With Israel
- Trump Media’s First Auditor Quits After Just a Few Months on the Job: Report
- US Plans to Lift Tariff Exceptions to Dominant Chinese Solar Panel Imports as Biden Accuses Beijing of 'Cheating' on Its Steel Trade Pactices
- Tesla Spends $200,000 in Promoting Elon Musk's Social Media Platform X Following Mention of 'Minimal Advertising Efforts'
- American Airlines Pilots Union Issues Urgent Safety Alert Over Maintenance Issues
- US Report: North Korea Producing Viruses, Bacteria for Germ Warfare Program
